Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BLI1100
- Development stage
- Phase 2
- Lead developer
- Braintree
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
BLI1100 is a topical small molecule drug developed for the treatment of moderate to severe acne vulgaris. It has been evaluated in clinical trials as a topical formulation intended to reduce the severity of facial acne. The drug was developed by Braintree Laboratories and has reached Phase 2 clinical development. Its precise mechanism of action and molecular target have not been publicly disclosed.
- Other names
- BLI1100-3BLI-1100-3BLI 1100-3
Beyond the preview
Go deeper on BLI1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BLI1100.